Anti‐IL‐31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice
Open Access
- 19 June 2014
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 171 (22), 5049-5058
- https://doi.org/10.1111/bph.12823
Abstract
Background and Purpose IL‐31, which is described as a pruritogenic cytokine, is linked to the itching that is associated with allergic and non‐allergic eczema, but the precise pruritogenic mechanism of IL‐31 and its potential as a therapeutic target for atopic dermatitis (AD) have not been determined. Experimental Approach We investigated the effects of existing drugs on the scratching behaviour induced by an i.v. injection of IL‐31 to clarify whether IL‐31 induced pruritus indirectly. In addition, we studied the effects of an anti‐IL‐31 receptor α subunit (anti‐IL‐31 receptor α) neutralizing antibody on chronic pruritus‐inducing dermatitis in an AD‐like model to determine whether IL‐31 not only induces scratching behaviour, but is also the causative factor in an AD phenotype. Key Results The scratching behaviour induced by an i.v. injection of IL‐31 was inhibited by pretreatment with an anti‐IL‐31 receptor α‐neutralizing antibody. In contrast, it was not inhibited significantly by a non‐sedative antihistamine (terfenadine), immunosuppressants (dexamethasone and tacrolimus), or a μ‐opioid receptor antagonist (naloxone). The anti‐IL‐31 receptor α‐neutralizing antibody reduced the ear swelling and dermatitis score in a chronic pruritus‐inducing AD‐like model. Moreover, treatment with the anti‐IL‐31 receptor α‐neutralizing antibody showed therapeutic effects on the dermatitis even if it was injected after the disease had developed. Conclusions and Implications Anti‐IL‐31 receptor α is a potential novel therapeutic approach for escaping from the itch–scratch cycle and also a treatment for dermatitis in AD.Keywords
This publication has 59 references indexed in Scilit:
- Serum measurement of interleukin‐31 (IL‐31) in paediatric atopic dermatitis: elevated levels correlate with severity scoringJournal of the European Academy of Dermatology and Venereology, 2011
- Pruritus: an overview of current conceptsVeterinary Dermatology, 2011
- Guidelines for reporting experiments involving animals: the ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Proteomic Approach to FcεRI Aggregation-Initiated Signal Transduction Cascade in Human Mast CellsInternational Archives of Allergy and Immunology, 2009
- Structures and biological functions of IL-31 and IL-31 receptorsCytokine & Growth Factor Reviews, 2008
- Frontiers in pruritus research: scratching the brain for more effective itch therapyJCI Insight, 2006
- Astilbin inhibits contact hypersensitivity through negative cytokine regulation distinct from cyclosporin AJournal of Allergy and Clinical Immunology, 2005
- Topical tacrolimus for the treatment of inflammatory skin diseasesExpert Opinion on Pharmacotherapy, 2001
- In vitro effects of H1-antihistamines on histamine and PGD2release from mast cells of human lung, tonsil, and skinAllergy, 1994